Does Rallies show Form 4 insider transactions for AVAH?

Yes. Rallies tracks AVAH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AVAH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AVAH. It does not provide personalized investment advice.

AVAH (Aveanna Healthcare Holdings Inc. Common Stock) Stock Analysis - Insider Trades

Aveanna Healthcare Holdings Inc. Common Stock (AVAH) is a publicly traded Healthcare sector company. As of May 21, 2026, AVAH trades at $7.50 with a market cap of $1.68B and a P/E ratio of 6.83. AVAH moved +0.66% today. Year to date, AVAH is -6.57%; over the trailing twelve months it is +33.57%. Its 52-week range spans $3.67 to $10.32. Analyst consensus is buy with an average price target of $9.94. Rallies surfaces AVAH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AVAH stock inside the company?

Recent AVAH insider activity includes Shaner Jeff sold 173.22K, Cunningham Patrick A. sold 18.44K, Buckhalter Matthew sold 13.51K, Stewart Deborah sold 11.18K, and Reisz Edwin C. sold 60.77K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AVAH Key Metrics

Key financial metrics for AVAH
Metric	Value
Price	$7.50
Market Cap	$1.68B
P/E Ratio	6.83
EPS	$1.11
Dividend Yield	0.00%
52-Week High	$10.32
52-Week Low	$3.67
Volume	1.14K
Avg Volume	0
Revenue (TTM)	$2.43B
Net Income	$225.03M
Gross Margin	33.31%

Recent AVAH Insider Trades

Shaner Jeff sold 173.22K (~$1.25M) on Feb 19, 2026.
Cunningham Patrick A. sold 18.44K (~$132.89K) on Feb 19, 2026.
Buckhalter Matthew sold 13.51K (~$97.40K) on Feb 19, 2026.
Stewart Deborah sold 11.18K (~$80.59K) on Feb 19, 2026.
Reisz Edwin C. sold 60.77K (~$438.04K) on Feb 19, 2026.

Latest AVAH News

Aveanna Raises 2026 Revenue Guidance to $2.56–2.58B, Targets $328M–332M EBITDA — May 15, 2026
Aveanna Healthcare Q1 EPS of $0.18 Beats by $0.05, Raises Guidance — May 14, 2026
Aveanna Q4 EBITDA Jumps 54% to $85M; Family First Deal Adds $120M — Mar 19, 2026
Aveanna Lifts 2025 Revenue to $2.425–2.445B and Adjusted EBITDA to $318–322M; 2026 Revenue Seen at $2.54–2.56B — Jan 14, 2026
Aveanna Healthcare CEO Offloads 29,357 Shares for $230,452, Cutting Stake by 1.21% — Jan 3, 2026

AVAH Analyst Consensus

9 analysts cover AVAH: 0 strong buy, 6 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.94.

Common questions about AVAH

Who is trading AVAH stock inside the company?: Recent AVAH insider activity includes Shaner Jeff sold 173.22K, Cunningham Patrick A. sold 18.44K, Buckhalter Matthew sold 13.51K, Stewart Deborah sold 11.18K, and Reisz Edwin C. sold 60.77K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AVAH?: Yes. Rallies tracks AVAH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AVAH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AVAH. It does not provide personalized investment advice.